Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared a post on LinkedIn:
“Last week at Milken Institute’s Future of Heath Summit in DC, I joined a panel to discuss the evolving landscape of precision medicine.
The headline: precision medicine is transforming cancer care, and the next wave of innovation will reshape what’s possible for patient communities.
What’s driving this change? New technologies, especially artificial intelligence. AI can turn complex, multimodal data into actionable insights, helping researchers and clinicians make more effective, timely,and equitable decisions.
What still needs to change? To create a future where cancer is no longer a cause of death, precision medicine must become the standard of care for all. Breakthrough therapies must be paired with equally innovative strategies to ensure access for all patients, including policies that make biomarker testing routine and support clinicians using these tools.
Thank you to Alice Park, Deborah Brooks, Lucy Chappell, and Beth Meagher for the great conversation. I’m energized by what’s ahead and optimistic about what we can accomplish together.”
More posts featuring Mohit Manrao.